Sabby Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-542
Closed -$6.35M 185
2017
Q3
$6.35M Sell
542
-821
-60% -$105K 0.42% 32
2017
Q2
$17.7M Sell
1,363
-47
-3% -$5.86K 1.16% 16
2017
Q1
$19.1M Buy
1,410
+1,147
+436% +$174K 1.03% 18
2016
Q4
$3.77M Buy
+263
New +$33.6K 0.22% 68
2016
Q2
Sell
-750
Closed -$8.36M 332
2016
Q1
$8.36M Sell
750
-28
-4% -$3.54K 0.42% 30
2015
Q4
$12.2M Sell
778
-140
-15% -$20.4K 0.67% 25
2015
Q3
$12M Buy
918
+382
+71% +$61.3K 0.5% 34
2015
Q2
$9.32M Buy
+536
New +$96.4K 0.34% 64
2015
Q1
Sell
-1,981
Closed -$25.7K 325
2014
Q4
$25.7K Buy
1,981
+1,111
+128% +$143K 0.81% 20
2014
Q3
$11.2K Buy
870
+481
+124% +$49.6K 0.43% 38
2014
Q2
$3.44M Sell
389
-121
-24% -$11.6K 0.15% 75
2014
Q1
$4.8M Buy
+510
New +$52.2K 0.27% 66
2013
Q4
Sell
-168
Closed -$1.32M 244
2013
Q3
$1.32M Buy
+168
New +$12.3K 0.09% 110

Other funds holding UTHR

Sabby Management's UTHR Position: Q3 2017 in Review

Sabby Management sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 53,116 shares — an estimated $6.78M sold.

Sabby Management first reported a position in UTHR in Q4 2015 and held it in 4 quarters. The position peaked at $6.89M in Q2 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Sabby Management reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 53,116 United Therapeutics shares in Q3 2017, an estimated $6.78M.
  • Sabby Management first reported a position in United Therapeutics in Q4 2015 and held it in 4 quarters.
  • Sabby Management's United Therapeutics position peaked at $6.89M in Q2 2017.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.